*Refresh the page if the below document does not appear.
Amneal Pharma begins its commercial operations in India
The beginning of Amneal Pharmaceuticals’ commercial operations in India has been announced. Amneal has appointed Mr. Shyamakant Giri as Managing Director and President, India Business and Emerging Markets to lead its India Commercial operations.
Maiden Pharma's MD says their drugs not responsible for children death in Gambia
MD of Maiden Pharma exclaimed that Medicines Control Agency (the national medicines regulator of Gambia) just recalled their products. A quality control analysis is being conducted by the Government of Gambia and before the results are published it is not right to publicly taint the image of his company.
Indian Pharma seeks US FDA's competitive generic therapies guidance
To accelerate the development process and the review of ANDAs (Abbreviated New Drug Applications), Indian Pharma companies are seeing US FDAs competitive generic therapies guidance owing to which the process of approvals will become easier.
Haryana Govt puts a halt to production of cough syrups by Maiden Pharma
After finding 12 flaws in a joint inspection conducted by the central and the state drug control department, Haryana Govt. ordered to completely stop the production of cough syrups that were flagged to be “substandard” and “contaminated” and potentially linked to the 66 children’s death in the Gambia.
BeiGene's new product Brukinsa all set to compete against AbbVie and J&J's Imbruvica
BeiGene has put forward evidence that shows its new product has BTK inhibitor that can fight certain blood cancers. Brukinsa beat Imbruvica at preventing the progression of disease or death in patients having chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) treatment history.
"5C Network" Digital diagnostic startup raises $4.6 million in funding
The leading Indian online medical diagnostics platform was recently able to raise 4.6 million USD in Series A financing facilitated by deep tech venture capital firm, Celesta Capital, with existing investors co-participating in the round, along with some significant angel investors.
Rosche attempts to sell Evrysdi win in previously treated SMA patients
With the collected positive data from the biggest
and most diverse study ever done in previously
treated SMA (Spinal Muscular Atrophy) patients,
Rosche is strengthening its case for Evrysdi in
people who may already have received
expensive therapies for their condition.
